Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 16, 2025

CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience

RRID:AB_468854
Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 16-0037-81, RRID:AB_468854)

Antibody Information

URL: http://antibodyregistry.org/AB_468854

Proper Citation: (Thermo Fisher Scientific Cat# 16-0037-81, RRID:AB_468854)

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow (0.25 µg/test), FN (Assay-Dependent)
Consolidation on 1/2020: AB_468854, AB_10116010

Antibody Name: CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_468854

Vendor: Thermo Fisher Scientific

Catalog Number: 16-0037-81

Record Creation Time: 20231110T080855+0000

Record Last Update: 20241114T234326+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Deng S, et al. (2024) ITPRIPL1 binds CD3? to impede T cell activation and enable tumor immune evasion. Cell, 187(9), 2305.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. Cell reports, 43(12), 115015.

Tachi T, et al. (2024) Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Cancer immunology, immunotherapy : CII, 73(12), 256.

Li L, et al. (2024) Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer. International journal of surgery (London, England), 110(8), 4716.

Zhou W, et al. (2024) Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment. Cell reports, 43(2), 113797.

Yan L, et al. (2024) Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion. Cancer research, 84(8), 1270.

Selvin T, et al. (2024) Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment. BMC pharmacology & toxicology, 25(1), 25.

King LA, et al. (2024) Leveraging V?9V?2 T cells against prostate cancer through a VHH-based PSMA-V?2 bispecific T cell engager. iScience, 27(12), 111289.

Kamnev A, et al. (2024) Coordinated ARP2/3 and glycolytic activities regulate the morphological and functional fitness of human CD8+ T cells. Cell reports, 43(3), 113853.

Mocholi E, et al. (2023) Pyruvate metabolism controls chromatin remodeling during CD4+ T cell activation. Cell reports, 42(6), 112583.

Choi SJ, et al. (2023) KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans. Cell reports, 42(3), 112236.

Nava Lauson CB, et al. (2023) Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. Cell metabolism, 35(4), 633.

Selvin T, et al. (2023) Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death. BMC cancer, 23(1), 164.

Kumagai S, et al. (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer cell, 40(2), 201.

Yang Z, et al. (2022) Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer discovery, 12(8), 1942.

Hanada KI, et al. (2022) A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer cell, 40(5), 479.

Nagasaki J, et al. (2022) PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell reports, 38(5), 110331.

Yang C, et al. (2022) Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity, 55(7), 1268.

Chan KL, et al. (2022) Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. Cancer cell, 40(10), 1190.